$6.94
2.81% yesterday
Nasdaq, Sep 26, 10:10 pm CET
ISIN
US8269171067
Symbol
SIGA

SIGA Technologies Inc Stock News

Neutral
PRNewsWire
about 12 hours ago
NEW YORK , Sept. 26, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company") SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small a...
Neutral
Seeking Alpha
about one month ago
SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients failed to meet its primary endpoint but showed safety. SIGA's reliance on US government contracts, especially for TPOXX, introduces substantial revenue concentration risk.
Negative
Invezz
about one month ago
The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to spread across countries in Africa and possibly outside the continent.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced topline results from a preliminary analysis of the PALM 007 (Tecovirimat for Treatment of Monkeypox Virus) clinical trial (NCT05559099). NIAID reported that the study did not meet its primary endpoint of a statistically significant i...
Neutral
Seeking Alpha
about 2 months ago
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Daniel Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Operator Welcome to SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking stateme...
Neutral
GlobeNewsWire
2 months ago
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
Neutral
GlobeNewsWire
3 months ago
Further Advances SIGA's Strategy to Expand Access to TPOXX into More International Markets Further Advances SIGA's Strategy to Expand Access to TPOXX into More International Markets

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today